- Clone:
- REA693 | AC144
- Type of antibody:
- Primary antibodies, Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- FC, MC Glossary
- Select a conjugate:
- Select a size:
Related products for CD303 (BDCA-2) Antibody, anti-human, REAfinity™
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Cells were incubated with an excess of purified unconjugated CD303 (BDCA-2) (REA693) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
Flow cytometric comparison of different clones for CD303 (BDCA-2). Human peripheral blood mononuclear cells (PBMCs) were stained with CD303 (BDCA-2) antibodies and with a suitable counterstaining. As a control, CD303 (BDCA-2) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
Comparison of staining pattern on non-fixed and fixed cells using CD303 (BDCA-2) (REA693). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
CD303 (BDCA-2) antibodies have been used, for example, to identify, characterize, and enumerate plasmacytoid dendritic cells in whole blood of healthy and HIV-infected individuals, and for analyzing the role of DC-SIGN in HIV infection and transmission. Furthermore, CD303 (BDCA-2) antibodies have been used to identify and enumerate plasmacytoid dendritic cells in blood and bone marrow samples before and after hematopoietic stem cell mobilization or transplantation. CD303 (BDCA-2) antibodies have also been used for immunohistochemical staining, for example, to identify plasmacytoid dendritic cells in tissue sections from patients with different inflammatory skin diseases.
Clone REA693 recognizes the CD303 (BDCA-2) antigen which is expressed on human plasmacytoid dendritic cells in blood, lymphoid (e.g. tonsils and bone marrow), and non-lymphoid tissue. Specific expression allows direct identification of plasmacytoid dendritic cells using just one marker. CD303 (BDCA-2)+ plasmacytoid dendritic cells in blood and bone marrow are CD11c–, CD123high, CD4+, Lin–, CD45RA+, CD304 (BDCA-4/Neuropilin-1)+, CD141 (BDCA-3)low, CD1c (BDCA-1)–, CD14–, and CD2–. They express neither myeloid lineage markers (CD13, CD33) nor Fc receptors (CD32, CD64, FcRI). CD303 (BDCA-2) is strongly expressed on freshly isolated plasmacytoid dendritic cells but down-regulated within 48 hours of culturing. Unlike CD304 (BDCA-4/Neuropilin-1), CD303 (BDCA-2) is not detectable on ex vivo generated monocyte-derived or hematopoietic precursor cell-derived CD1a+ dendritic cells.
The CD303 (BDCA-2) antigen is a novel type II transmembrane C-type lectin. Remarkably, plasmacytoid dendritic cells can take up ligands via CD303 (BDCA-2), then process and present the ligands to T cells. Unlike binding of antibodies to CD304 (BDCA-4), binding of antibodies to CD303 (BDCA-2) inhibits type I IFN production, which is induced in plasmacytoid dendritic cells by, for example, the influenza virus.
Additional information: Clone REA693 displays negligible binding to Fc receptors.
BDCA-2
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
You have previously chosen International as your location.
What do you want to do?